Physicochemical Properties
| Molecular Formula | C20H22N4O |
| Molecular Weight | 334.41 |
| CAS # | 3032200-62-4 |
| PubChem CID | 163409096 |
| Appearance | Typically exists as solid at room temperature |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 25 |
| Complexity | 465 |
| Defined Atom Stereocenter Count | 0 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Triple-negative breast cancer (TNBC) cells have antiproliferative action against FAK-IN-4 (Compound 7d) (0-200 μM, 72 h)[1]. MDA-MB-231 cell migration and invasion are inhibited by FAK-IN-4 (0–20 μM, 24 h)[1]. FAK-IN-4 (0–20 μM, 72 h) dephosphorylates FAK in a dose-dependent manner and causes MDA-MB-231 cells to undergo apoptosis[1]. In MDA-MB-231 cells, FAK-IN-4 prevents the development of stress fibers (SFs) and focal adhesions (FAs)[1]. |
| Cell Assay |
Cell Proliferation Assay[1] Cell Types: MDA-MB-231, MDA- MB-157, MDA-MB-453 and MCF10A Tested Concentrations: 0.78, 1.56, 3.13, 5, 6.25, 100, 12.5, 25, 50, 100 and 200 μM Incubation Duration: 72 h Experimental Results: Inhibited the growth of TNBC cells with IC50 values of 8.37, 12.09, 9.07 and 40.63 μM against MDA-MB-231, MDA-MB-157, MDA-MB-453 and MCF10A cells. Cell Invasion Assay[1] Cell Types: MDA-MB-231 Tested Concentrations: 5, 10 and 20 μM Incubation Duration: 24 h Experimental Results: Dramatically inhibited the invasion of MDA-MB-231 cells in a dose-dependent manner. Western Blot Analysis[1] Cell Types: MDA-MB-231 Tested Concentrations: 5, 10 and 20 μM Incubation Duration: 72 h Experimental Results: Caused an obvious dose-dependent Y925 dephosphorylation of FAK. Apoptosis Analysis[1] Cell Types: MDA-MB-231 Tested Concentrations: 5, 10 and 20 μM Incubation Duration: 72 h Experimental Results: Increased the percentage of apoptotic MDA-MB-231 cells ranging from 13.10% to 41.59% in a dose-dependent manner. |
| References |
[1]. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer. Bioorg Med Chem. 2022 Jul 15;66:116809. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9903 mL | 14.9517 mL | 29.9034 mL | |
| 5 mM | 0.5981 mL | 2.9903 mL | 5.9807 mL | |
| 10 mM | 0.2990 mL | 1.4952 mL | 2.9903 mL |